Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor by Anita Moein, Jin Y. Jin, Matthew R. Wright, Bruno Alicke, Harvey Wong

Connect to this object online.

A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score by Anita Moein, Jurgen Langenhorst, Elodie L. Plan, Jin Y. Jin, Matts Kågedal, Nastya Kassir

Connect to this object online.

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis by Nastya Kassir, Rui Zhu, Anita Moein, Jurgen Langenhorst, Jakob Ribbing, Rong Zhang, Meina T. Tang, Young S. Oh, Wenhui Zhang

Connect to this object online.

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis by Anita Moein, Tong Lu, Siv Jönsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina Tang, Young S. Oh, Rene Bruno, Rui Zhu

Connect to this object online.

First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers by Fei Tang, Rebecca Kunder, Tom Chu, Avis Hains, Allen Nguyen, Jacqueline M. McBride, Yu Zhong, Sara Santagostino, Maria Wilson, Abigail Trenchak, Liuxi Chen, Justin Ly, Anita Moein, Nicholas Lewin‐Koh, Vibha Raghavan, Uyi Osaghae, Chris Wynne, Ryan Owen, David Place

Connect to this object online.